for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ALX Oncology Holdings Inc

ALXO.OQ

Latest Trade

77.81USD

Change

-3.10(-3.83%)

Volume

477,037

Today's Range

76.81

 - 

81.19

52 Week Range

32.72

 - 

117.15

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
80.91
Open
81.19
Volume
477,037
3M AVG Volume
6.21
Today's High
81.19
Today's Low
76.81
52 Week High
117.15
52 Week Low
32.72
Shares Out (MIL)
40.34
Market Cap (MIL)
3,139.07
Forward P/E
-43.84
Dividend (Yield %)
--

Next Event

ALX Oncology Holdings Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual)

Latest Developments

More

ALX Oncology Reports Second Quarter 2021 Financial Results

ALX Oncology Announces New Data From Phase 1B Study Of ALX148

ALX Oncology Reports Q1 GAAP Loss Per Share Of $0.35

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ALX Oncology Holdings Inc

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company. The Company is focused on enabling patients to fight cancer by developing therapies that block the cluster of differentiation 47 (CD47) checkpoint pathway and bridge the innate and adaptive immune system. The Company is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead product candidate, ALX148, is a CD47 blocking therapeutic. ALX148 is a fusion protein that combines a CD47 binding domain with its inactivated fragment crystallizable (Fc) domain. The CD47 binding domain of ALX148 is an affinity enhanced extracellular domain of signal regulatory protein alpha (SIRPa), a protein that is the natural receptor to CD47 found on myeloid cells. Its programs are focused on targeting CD47 across various oncology indications.

Industry

Biotechnology & Drugs

Contact Info

866 Malcolm Road, Suite 100

BURLINGAME, CA

94010

United States

+1.650.4667125

http://alxoncology.com/

Executive Leadership

Corey S. Goodman

Executive Chairman of the Board

Jaume Pons

President, Chief Executive Officer, Director

Peter S. Garcia

Chief Financial Officer

Shelly Pinto

Chief Accounting Officer, Vice President - Finance

Sophia Randolph

Chief Medical Officer, Director

Key Stats

1.86 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2020

0.0K

2021(E)

0.0K
EPS (USD)

2020

-2.720

2021(E)

-1.784
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
7.75
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.23
LT Debt To Equity (MRQ)
0.12
Return on Investment (TTM)
-23.64
Return on Equity (TTM)
-22.66

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up